In T2DM patients with existing coronary heart disease , short-term rosiglitazone treatment caused minor improvements in metabolism : serum lactate and glutamine concentrations changed , reflecting improvements in insulin sensitivity , and circulating lactate concentrations inversely correlated to increases in myocardial glucose uptake .